Company news
Precigen, Inc. news in 2023
Precigen, Inc.'s news releases, calls and decks from 2023, newest first.
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 17, 2023
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
November 28, 2023
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
November 8, 2023
Precigen to Participate in the Stifel 2023 Healthcare Conference
November 6, 2023
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
September 18, 2023
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
August 8, 2023
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
August 8, 2023
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
August 2, 2023
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
June 19, 2023
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
June 4, 2023
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
June 2, 2023
Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer
May 30, 2023
Precigen Reports First Quarter 2023 Financial Results and Business Updates
May 9, 2023
Precigen to Announce First Quarter 2023 Financial Results on May 10th
May 2, 2023
Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting
April 25, 2023
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
April 16, 2023
Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®
April 2, 2023
Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors
March 28, 2023
Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium
March 27, 2023
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
March 5, 2023
Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response
February 6, 2023
Precigen Announces Closing of Public Offering of Common Stock
January 26, 2023
Precigen Announces Proposed $75.0 Million Public Offering of Common Stock
January 23, 2023
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock
January 23, 2023
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
January 23, 2023
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
January 10, 2023
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis
January 3, 2023